(Q35765903)

10 August 2017

1 reference

title

The effect of antiepileptic drugs on visual performance (English)

1 reference

10 August 2017

Emma J Roff Hilton

1

1 reference

10 August 2017

Sarah L Hosking

series ordinal

2

1 reference

10 August 2017

Tim Betts

series ordinal

3

1 reference

10 August 2017

publication date

1 March 2004

1 reference

Seizure-European Journal of Epilepsy

10 August 2017

published in

1 reference

10 August 2017

volume

13

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

113-128

1 reference

Clinical ictal patterns in epileptic patients with occipital electroencephalographic foci.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The influence of established and new antiepileptic drugs on visual perception. 1. A placebo-controlled, double-blind, single-dose study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

GABA transporter heterogeneity: pharmacology and cellular localization

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

1 reference

7 January 2021

Localization of GABA, glycine, glutamate and tyrosine hydroxylase in the human retina

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Glutamate and GABA in retinal circuitry

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Diversity of GABA receptors in the vertebrate outer retina

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Different contributions of GABAA and GABAC receptors to rod and cone bipolar cells in a rat retinal slice preparation

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

GABA-gated Cl- channels in the rat retina

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Immunocytochemical localization of the GABAc receptor rho subunits in the mammalian retina

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Expression of GABA transporter subtypes (GAT1, GAT3) in the adult rabbit retina

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

1 reference

7 January 2021

Characteristics of a unique visual field defect attributed to vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

1 reference

7 January 2021

Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Effects of antiepileptic drugs on visual function, with special reference to Vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual field constriction and electrophysiological changes associated with vigabatrin.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Vigabatrin visual toxicity: evolution and dose dependence

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual field constriction in 91 Finnish children treated with vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Severe persistent visual field constriction associated with vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

No reversion in vigabatrin-associated visual field defects

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Reversed visual field constrictions in children after vigabatrin withdrawal--true retinal recovery or improved test performance only?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual field and electrophysiological abnormalities due to vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Patients treated with vigabatrin exhibit central visual function loss

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The effect on vision of associated treatments in patients taking vigabatrin: carbamazepine versus valproate

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Epilepsy patients treated with antiepileptic drug therapy exhibit compromised ocular perfusion characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

A controlled study of vigabatrin and visual abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Changes in color vision after a single dose of vigabatrin or carbamazepine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The influence of established and new antiepileptic drugs on visual perception. II. A controlled study in patients with epilepsy under long-term antiepileptic medication.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Short-wavelength sensitive visual field loss in patients with clinically significant diabetic macular oedema.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Effect of long-term vigabatrin administration on the immature rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The potential for vigabatrin-induced intramyelinic edema in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Vigabatrin-induced optic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual field defects associated with vigabatrin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual field loss associated with vigabatrin: pathological correlations

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Vigabatrin effect on inner retinal function

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual electrophysiological effect of a GABA transaminase blocker

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual field defects with vigabatrin: epidemiology and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual function loss from vigabatrin: effect of stopping the drug

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

A pharmacological and clinical review on topiramate, a new antiepileptic drug

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Topiramate-associated secondary angle-closure glaucoma: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Distribution of topiramate in a medical examiner's case

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Safety of tiagabine: summary of 53 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Safety of long-term treatment with tiagabine

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual fields and tiagabine: a quandary

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The effects of GABA and related drugs on horizontal cells in the isolated turtle retina.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The role of GABA in modulating the Xenopus electroretinogram

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Valproate induced changes in GABA metabolism at the subcellular level

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The effect of anti-epileptic drugs on visual perception in patients with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Color vision tests for early detection of antiepileptic drug toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Assessment of colour vision in epileptic patients exposed to single-drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Suppression by sodium valproate of gamma-vinyl GABA-induced facilitation of visual evoked potentials in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Pharmacologic analysis of sodium valproate-induced suppression of secondary components of visual evoked potentials in albino rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Effects of antiepileptic drugs on evoked potentials in epileptic children.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual functions in epilepsy patients on valproate monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Newer antiepileptic drugs: advantages and disadvantages

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Reversible downbeat nystagmus and ataxia in felbamate intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Benzodiazepines and the mammalian retina. I. Autoradiographic localisation of receptor sites and the lack of effect on the electroretinogram

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Alterations in transient visual-evoked potentials induced by clonazepam and sodium valproate.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Effects of the anticonvulsant benzodiazepine clonazepam on event-related brain potentials in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The effect of long-term use of benzodiazepines on the eye and retina

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The comparability of rat and human visual-evoked potentials

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Effects of single doses of diazepam, chlorpromazine, imipramine and trihexyphenidyl on visual-evoked potentials

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Questions concerning the effect by diazepam (Faustan) in the EOG (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Maculopathy associated with diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Allergic conjunctivitis due to diazepam

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Diazepam and its effects on visual fields

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The effect of diazepam on nystagmus induced by stimulation of the lateral geniculate body in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Barbiturate reduction of calcium-dependent action potentials: Correlation with anesthetic action

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Effects of chronic high serum levels of phenobarbital on evoked potentials in epileptic children

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Phenytoin and carbamazepine: potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side effects in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Possible retinotoxic effect of carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual and ocular outcome in children after prenatal exposure to antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Oxcarbazepine, an antiepileptic agent

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Effects of oxcarbazepine and carbamazepine on the central nervous system: computerised analysis of saccadic and smooth-pursuit eye movements

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

A pilot study of gabapentin as treatment for acquired nystagmus.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Pendular nystagmus in patients with peroxisomal assembly disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Neuro-ophthalmological signs during rapid intravenous administration of phenytoin.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

The tolerability of lamotrigine in children

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Lamotrigine overdose in an adult

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Comparison of the effects of lamotrigine and phenytoin on the EEG power spectrum and cortical and brainstem-evoked responses of normal human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Visual field constriction is not limited to children treated with vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

Long-term continuation of levetiracetam in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900082-7

7 January 2021

10.1016/S1059-1311(03)00082-7

Identifiers

DOI

1 reference

10 August 2017

1 reference